PMID: 8610107Apr 2, 1996Paper

Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain

Proceedings of the National Academy of Sciences of the United States of America
M HoshiK Imahori

Abstract

According to the amyloid hypothesis for the pathogenesis of Alzheimer disease, beta-amyloid peptide (betaA) directly affects neurons, leading to neurodegeneration and tau phosphorylation. In rat hippocampal culture, betaA exposure activates tau protein kinase I/glycogen synthase kinase 3beta (TPKI/GSK-3beta), which phosphorylates tau protein into Alzheimer disease-like forms, resulting in neuronal death. To elucidate the mechanism of betaA-induced neuronal death, we searched for substrates of TPKI/GSK-3beta in a two-hybrid system and identified pyruvate dehydrogenase (PDH), which converts pyruvate to acetyl-CoA in mitochondria. PDH was phosphorylated and inactivated by TPKI/GSK-3beta in vitro and also in betaA-treated hippocampal cultures, resulting in mitochondrial dysfunction, which would contribute to neuronal death. In cholinergic neurons, betaA impaired acetylcholine synthesis without affecting choline acetyltransferase activity, which suggests that PDH is inactivated by betaA-induced TPKI/GSK-3beta. Thus, TPKI/GSK-3beta regulates PDH and participates in energy metabolism and acetylcholine synthesis. These results suggest that TPKI/GSK-3beta plays a key role in the pathogenesis of Alzheimer disease.

References

Mar 26, 1977·Lancet·P WhiteD M Bowen
Nov 3, 1977·Nursing Mirror·S Powter
Apr 10, 1992·Science·J A Hardy, G A Higgins
Apr 1, 1991·Neuron·D J Selkoe
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·K S KosikD J Selkoe
Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·I Grundke-IqbalL I Binder
Feb 1, 1970·The Journal of Cell Biology·D W McKeel, L Jarett
Apr 23, 1982·Science·R G StrubleD L Price
Aug 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A TakashimaK Imahori

❮ Previous
Next ❯

Citations

Oct 8, 1999·European Journal of Drug Metabolism and Pharmacokinetics·G Wu
Jun 10, 2009·Molecular Neurobiology·Jia Luo
Jan 11, 2001·Pharmacology & Therapeutics·K Yamada, T Nabeshima
Feb 17, 1998·Trends in Neurosciences·D S AuldR Quirion
Nov 28, 2002·Advanced Drug Delivery Reviews·Pierre N TariotSaleem Ismail
Feb 19, 2002·Neurochemistry International·Gary E Gibson, Hui Zhang
Apr 30, 1998·Neurobiology of Aging·K ImahoriT Uchida
Aug 31, 2001·Progress in Neurobiology·C A Grimes, R S Jope
Jul 22, 1998·Progress in Neurobiology·B H AndertonC Weaver
Sep 17, 1998·Brain Research Bulletin·G M BoresA Giovanni
Aug 18, 1999·Journal of Chemical Neuroanatomy·K Leroy, J P Brion
Aug 27, 2005·Mitochondrion·Daciana H MargineantuRoderick A Capaldi
Nov 26, 2010·Nature Biotechnology·Nathan E LewisBernhard Ø Palsson
Mar 2, 1999·British Journal of Pharmacology·K YamadaT Nabeshima
Feb 1, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jorge A QuirozHusseini K Manji
Oct 3, 2003·The Journal of Biological Chemistry·Piyajit WatcharasitRichard S Jope
Sep 10, 2002·Alzheimer Disease and Associated Disorders·Guilian XuDavid R Borchelt
Jul 28, 2011·Molekuliarnaia biologiia·E V FilatovaS A Limborskaia
Nov 21, 2009·Molecular Brain·Oksana Kaidanovich-BeilinJames R Woodgett
Nov 12, 2013·Reviews in Endocrine & Metabolic Disorders·Nam Ho JeoungRobert A Harris
Sep 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·R V BhatC M Lee
May 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Minako HoshiKazuki Sato
May 11, 2000·Proceedings of the National Academy of Sciences of the United States of America·Y KashiwayaR L Veech
Aug 5, 1998·Proceedings of the National Academy of Sciences of the United States of America·A TakashimaB Wolozin
Jun 2, 2011·International Journal of Alzheimer's Disease·Calum Sutherland
Jul 16, 2010·Metabolomics : Official Journal of the Metabolomic Society·Teresa W-M FanRima Kaddurah-Daouk
Dec 17, 2014·Current Opinion in Biotechnology·Annalisa ZecchinPeter Carmeliet
Sep 2, 2005·Journal of Neurochemistry·Tomas Dobransky, R Jane Rylett
Apr 23, 2005·The European Journal of Neuroscience·Katarina G BryweHenrik Hagberg
Dec 20, 2007·Journal of Neurochemistry·Claudie HooperSimon Lovestone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.